Observations at VA shows Merck's Zepatier has high SVR for HCV
Merck announced the presentation of findings from a retrospective database analysis of patients with chronic hepatitis C virus, HCV, infection who were administered ZEPATIER in the U.S. Department of Veterans Affairs, VA, healthcare system. For the evaluable population, 95.6% of veterans treated with ZEPATIER achieved the primary outcome of sustained virologic response, SVR, defined as undetectable HCV RNA at least twelve weeks after the end of treatment. For patients with no HCV RNA measurements at or after 12 weeks, the analysis used HCV RNA measurements available at least four and less than 12 weeks after the end of treatment. The response rates in the real-world setting of the VA supplement the overall findings from the controlled clinical studies of ZEPATIER. These findings will be presented today in an oral session at The International Liver Congress 2017 being held in Amsterdam, the Netherlands. Analysis of data from real-world medical settings can provide useful insights to supplement knowledge gained from randomized clinical trials," said Susan Shiff, senior vice president, center for observational and real-world evidence, Merck. "These data from a real-world VA setting add to the body of evidence on ZEPATIER and help deepen scientific understanding of the treatment of this complex disease affecting diverse, sometimes difficult to treat, patient populations."